Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development
Hyperlipidemia or dyslipidemia is a major risk factor for atherosclerotic diseases. Experimental animals play an important role in elucidating the molecular mechanisms of the pathophysiology of hyperlipidemia as well as in drug development. Rabbits are one of the most suitable models to study human...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/10/23/8681 |
| _version_ | 1797545753295454208 |
|---|---|
| author | Manabu Niimi Yajie Chen Haizhao Yan Yao Wang Tomonari Koike Jianglin Fan |
| author_facet | Manabu Niimi Yajie Chen Haizhao Yan Yao Wang Tomonari Koike Jianglin Fan |
| author_sort | Manabu Niimi |
| collection | DOAJ |
| description | Hyperlipidemia or dyslipidemia is a major risk factor for atherosclerotic diseases. Experimental animals play an important role in elucidating the molecular mechanisms of the pathophysiology of hyperlipidemia as well as in drug development. Rabbits are one of the most suitable models to study human hyperlipidemia because many features of the lipoprotein metabolism of rabbits are similar to those of humans such as LDL-rich lipoproteins in plasma, apolipoprotein B mRNA editing, and cholesteryl ester transfer protein. Currently, three types of rabbit models are commonly used for studying hyperlipidemia: (1) diet-induced hyperlipidemic rabbits, (2) spontaneous hyperlipidemic rabbits, and (3) gene-manipulated rabbits (transgenic and knockout rabbits). In this review, we give an overview of the features of hyperlipidemic rabbits and discuss the usefulness of rabbits for the development of anti-atherogenic drugs. |
| first_indexed | 2024-03-10T14:19:24Z |
| format | Article |
| id | doaj.art-60904fd279f34875ac82405b01b2b133 |
| institution | Directory Open Access Journal |
| issn | 2076-3417 |
| language | English |
| last_indexed | 2024-03-10T14:19:24Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj.art-60904fd279f34875ac82405b01b2b1332023-11-20T23:29:10ZengMDPI AGApplied Sciences2076-34172020-12-011023868110.3390/app10238681Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug DevelopmentManabu Niimi0Yajie Chen1Haizhao Yan2Yao Wang3Tomonari Koike4Jianglin Fan5Department of Molecular Pathology, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, JapanDepartment of Molecular Pathology, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, JapanDepartment of Molecular Pathology, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, JapanSchool of Biotechnology and Health Sciences, Wuyi University, Jiangmen, Guangdong 529020, ChinaDepartment of Molecular Pathology, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, JapanDepartment of Molecular Pathology, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, JapanHyperlipidemia or dyslipidemia is a major risk factor for atherosclerotic diseases. Experimental animals play an important role in elucidating the molecular mechanisms of the pathophysiology of hyperlipidemia as well as in drug development. Rabbits are one of the most suitable models to study human hyperlipidemia because many features of the lipoprotein metabolism of rabbits are similar to those of humans such as LDL-rich lipoproteins in plasma, apolipoprotein B mRNA editing, and cholesteryl ester transfer protein. Currently, three types of rabbit models are commonly used for studying hyperlipidemia: (1) diet-induced hyperlipidemic rabbits, (2) spontaneous hyperlipidemic rabbits, and (3) gene-manipulated rabbits (transgenic and knockout rabbits). In this review, we give an overview of the features of hyperlipidemic rabbits and discuss the usefulness of rabbits for the development of anti-atherogenic drugs.https://www.mdpi.com/2076-3417/10/23/8681rabbithyperlipidemialipoproteinapolipoproteindrug development |
| spellingShingle | Manabu Niimi Yajie Chen Haizhao Yan Yao Wang Tomonari Koike Jianglin Fan Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development Applied Sciences rabbit hyperlipidemia lipoprotein apolipoprotein drug development |
| title | Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development |
| title_full | Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development |
| title_fullStr | Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development |
| title_full_unstemmed | Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development |
| title_short | Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development |
| title_sort | hyperlipidemic rabbit models for anti atherosclerotic drug development |
| topic | rabbit hyperlipidemia lipoprotein apolipoprotein drug development |
| url | https://www.mdpi.com/2076-3417/10/23/8681 |
| work_keys_str_mv | AT manabuniimi hyperlipidemicrabbitmodelsforantiatheroscleroticdrugdevelopment AT yajiechen hyperlipidemicrabbitmodelsforantiatheroscleroticdrugdevelopment AT haizhaoyan hyperlipidemicrabbitmodelsforantiatheroscleroticdrugdevelopment AT yaowang hyperlipidemicrabbitmodelsforantiatheroscleroticdrugdevelopment AT tomonarikoike hyperlipidemicrabbitmodelsforantiatheroscleroticdrugdevelopment AT jianglinfan hyperlipidemicrabbitmodelsforantiatheroscleroticdrugdevelopment |